Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes

Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes

Recombinant adeno-associated virus (rAAV) vectors have been developed for therapeutic treatment of genetic diseases. Current rAAV vectors administered to affected individuals often contain vector DNA-related contaminants. Here we present a thorough molecular analysis of the configuration of non-stan...

Full description

Bibliographic Details
Main Authors:	Junping Zhang, Ping Guo, Xiangping Yu, Dylan A. Frabutt, Anh K. Lam, Patrick L. Mulcrone, Matthew Chrzanowski, Jenni Firrman, Derek Pouchnik, Nianli Sang, Yong Diao, Roland W. Herzog, Weidong Xiao
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Molecular Therapy: Nucleic Acids
Subjects:	MT: Oligonucleotides Therapies and Applications recombinant adeno-associated virus (rAAV) vectors subgenomic particles DNA lesion/break non-homologous end joining
Online Access:	http://www.sciencedirect.com/science/article/pii/S2162253122002268

Similar Items

CRISPR screen reveals modifiers of rAAV production including known rAAV infection genes playing an unexpected role in vector production
by: Emily E. O’Driscoll, et al.
Published: (2025-03-01)

High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector
by: Stefan Weger
Published: (2022-12-01)

Crucial aspects for maintaining rAAV stability
by: Johannes Lengler, et al.
Published: (2024-11-01)

Satellite Subgenomic Particles Are Key Regulators of Adeno-Associated Virus Life Cycle
by: Junping Zhang, et al.
Published: (2021-06-01)

Thorough molecular configuration analysis of noncanonical AAV genomes in AAV vector preparations
by: Junping Zhang, et al.
Published: (2024-03-01)

rAAV Manufacturing: The Challenges of Soft Sensing during Upstream Processing
by: Cristovão Freitas Iglesias, et al.
Published: (2023-02-01)

Monobac System–A Single Baculovirus for the Production of rAAV
by: Lionel Galibert, et al.
Published: (2021-08-01)

Performance of Cardiotropic rAAV Vectors Is Dependent on Production Method
by: Renuka Rao, et al.
Published: (2022-07-01)

Identification of the role of SNARE proteins in rAAV vector production through interaction with the viral MAAP
by: Cagla Aksu Kuz, et al.
Published: (2025-03-01)

Efficient construction of rAAV-based gene targeting vectors by Golden Gate cloning
by: Yonglun Luo, et al.
Published: (2014-05-01)

A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR
by: Junping Zhang, et al.
Published: (2024-03-01)

Adding recombinant AAVs to the cancer therapeutics mix
by: Patrick L. Mulcrone, et al.
Published: (2022-12-01)

Controlled Release of rAAV Vectors from APMA-Functionalized Contact Lenses for Corneal Gene Therapy
by: Fernando Alvarez-Rivera, et al.
Published: (2020-04-01)

Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells
by: Alok Tanala Patra, et al.
Published: (2024-09-01)

Immunosuppression reduces rAAV2.5T neutralizing antibodies that limit efficacy following repeat dosing to ferret lungs
by: Yinghua Tang, et al.
Published: (2023-06-01)

A comparison of the impact on neuronal transcriptome and cognition of rAAV5 transduction with three different doses in the mouse hippocampus
by: Yi-Si Liu, et al.
Published: (2023-07-01)

Gene Therapy in the Light of Lifestyle Diseases: Budesonide, Acetaminophen and Simvastatin Modulates rAAV Transduction Efficiency
by: Żaneta Słyk, et al.
Published: (2024-09-01)

Reactive oxygen species enhance rAAV transduction by promoting its escape from late endosomes
by: Xiaoping Huang, et al.
Published: (2023-01-01)

rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
by: Weiran Shen, et al.
Published: (2022-10-01)

Detection of Gene Doping Using Dried Blood Spots from a Mouse Model with rAAV9 Vector-Mediated Human Erythropoietin Expression as a Pilot Study
by: Norihiro Otani, et al.
Published: (2024-06-01)

The intersection of vector biology, gene therapy, and hemophilia
by: Leszek Lisowski, et al.
Published: (2021-08-01)

Corrigendum: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
by: Weiran Shen, et al.
Published: (2023-01-01)

Analysis of thermally driven structural changes, genome release, disassembly, and aggregation of recombinant AAV by CDMS
by: Lauren F. Barnes, et al.
Published: (2022-12-01)

Transgene distribution and immune response after ultrasound delivery of rAAV9 and PHP.B to the brain in a mouse model of amyloidosis
by: Rikke Hahn Kofoed, et al.
Published: (2021-12-01)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
by: Ilias B. Esmagambetov, et al.
Published: (2023-03-01)

Low endotoxin E. coli strain-derived plasmids reduce rAAV vector-mediated immune responses both in vitro and in vivo
by: Qingyun Zheng, et al.
Published: (2021-09-01)

Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno‐Associated Viral Vector rAAV9P1
by: Amelie Bauer, et al.
Published: (2022-05-01)

rAAV-mediated overexpression of TGF-β via vector delivery in polymeric micelles stimulates the biological and reparative activities of human articular chondrocytes in vitro and in a human osteochondral defect model
by: Rey-Rico A, et al.
Published: (2017-09-01)

rAAV2-Mediated Restoration of GALC in Neural Stem Cells from Krabbe Patient-Derived iPSCs
by: Guoshuai Tian, et al.
Published: (2023-04-01)

Probing recombinant AAV capsid integrity and genome release after thermal stress by mass photometry
by: Eduard H.T.M. Ebberink, et al.
Published: (2024-09-01)

Genome length determination in adeno-associated virus vectors with mass photometry
by: Cornelia Hiemenz, et al.
Published: (2023-12-01)

Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
by: Prabhakar Bastola, et al.
Published: (2020-08-01)

Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques
by: Liam Cole, et al.
Published: (2021-04-01)

A self-complementary AAV proviral plasmid that reduces cross-packaging and ITR promoter activity in AAV vector preparations
by: Noah K. Taylor, et al.
Published: (2024-09-01)

Adeno-Associated Virus (AAV) Versus Immune Response
by: Joseph Rabinowitz, et al.
Published: (2019-01-01)

A Comprehensive Study of the Effects by Sequence Truncation within Inverted Terminal Repeats (ITRs) on the Productivity, Genome Packaging, and Potency of AAV Vectors
by: Yinxing Chen, et al.
Published: (2024-02-01)

Pilot-scale process development for recombinant adeno-associated virus (rAAV) production based on high-density Sf9 cell culture
by: Xinran Li, et al.
Published: (2024-11-01)

Preclinical Assessment of Immune Responses to AAV (adeno-associated virus) Vectors
by: Etiena eBasner-Tschakarjan, et al.
Published: (2014-02-01)

Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes in vitro and in vivo
by: Alexandra L. Schober, et al.
Published: (2016-11-01)

Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein–Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV + lymphoproliferative disorders
by: Elham Ahmadi, et al.
Published: (2021-11-01)